MedDataX Logo

Effect of Bile Acids on the Secretion of Satiation Peptides in Humans

NCT ID: NCT01674946

Last Updated: 2012-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is do determine the functional significance of the G protein-coupled receptor TGR5 in the secretion of GI satiation peptides by using natural bile acids and oleanolic acid (triterpenoid compound of plant origin) as TGR5 agonists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Bile Acids in Patients With Peroxisomal Disorders

NCT00004442

Infantile Refsum's Disease Zellweger Syndrome Bifunctional Enzyme Deficiency +1 more
TERMINATED NA

Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

NCT05314374

Obesity Healthy
COMPLETED PHASE1

Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

NCT00706381

Healthy Volunteers
COMPLETED PHASE3

Obeticholic Acid in Bariatric and Gallstone Disease

NCT01625026

Obesity Gallstones
COMPLETED PHASE2

Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children

NCT04542473

SEPSIS MALNUTRITION, CHILD
UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TGR5 is expressed in GLP-1-secreting cell lines and L cells from mice; gain- and loss-of-function models suggest a physiological role for TGR5 activation on GLP-1 secretion in rodents. TGR5 signaling showed improved postprandial glucose tolerance in obese mice, associated with marked postprandial GLP-1 release and insulin secretion. In contrast, TGR5-/- mice exhibited reduced glucose tolerance. In animals, TGR5 activation has been shown for natural bile acids (BAs) and triterpenoid compounds of plant origin, such as oleanolic acid (OA), suggesting a role for postprandial BAs in modulating nutrient-induced GLP-1 secretion. We therefore hypothesized that intraduodenal (ID) perfusions of TGR5 agonists (BAs and OA) stimulate the secretion of GLP-1 with respective changes in the glucose metabolism of healthy humans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Echolocation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ID saline

ID saline by feeding tube

Group Type PLACEBO_COMPARATOR

saline

Intervention Type OTHER

intraduodenal perfusion

ID saline + CDCA (5 mmol/L)

CDCA = chenodeoxycholic acid (primary bile acid)

Group Type ACTIVE_COMPARATOR

saline

Intervention Type OTHER

intraduodenal perfusion

bile acid (CDCA, chenodeoxycholic acid)

Intervention Type OTHER

intraduodenal perfusion

ID + CDCA (15 mmol/L)

CDCA = chenodeoxycholic acid (primary bile acid)

Group Type ACTIVE_COMPARATOR

saline

Intervention Type OTHER

intraduodenal perfusion

bile acid (CDCA, chenodeoxycholic acid)

Intervention Type OTHER

intraduodenal perfusion

ID saline + oleanolic acid (1 mmol/L)

Group Type ACTIVE_COMPARATOR

saline

Intervention Type OTHER

intraduodenal perfusion

oleanolic acid

Intervention Type OTHER

intraduodenal perfusion

ID saline + CDCA (5 mmol/L) + oleic acid

Group Type ACTIVE_COMPARATOR

saline

Intervention Type OTHER

intraduodenal perfusion

bile acid (CDCA, chenodeoxycholic acid)

Intervention Type OTHER

intraduodenal perfusion

oleic acid

Intervention Type DIETARY_SUPPLEMENT

intraduodenal perfusion

ID saline + oleic acid (20 mmol/L)

Group Type PLACEBO_COMPARATOR

saline

Intervention Type OTHER

intraduodenal perfusion

oleic acid

Intervention Type DIETARY_SUPPLEMENT

intraduodenal perfusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

saline

intraduodenal perfusion

Intervention Type OTHER

bile acid (CDCA, chenodeoxycholic acid)

intraduodenal perfusion

Intervention Type OTHER

oleanolic acid

intraduodenal perfusion

Intervention Type OTHER

oleic acid

intraduodenal perfusion

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

primary bile acid triterpenoid compound of plant origin fatty acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects
* BMI of 19.0-24.5
* Age 18-40
* Stable body weight for at least 3 months

Exclusion Criteria

* Smoking
* Substance abuse
* Regular intake of medication
* Medical of psychiatric illness
* Gastrointestinal disorders or food allergies
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Beglinger, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Basel, Phase 1 Research Unit, Basel Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Basel, Phase 1 Research Unit

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EKBB 140/11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers
NCT01237353 COMPLETED NA
Regulation of Human Intestinal Bile Acid Transport in Health and Disease
NCT00018681 COMPLETED
Bile Acids As Determinants of Postprandial Metabolism
NCT06758453 ACTIVE_NOT_RECRUITING NA
The 8x5 Diet for Bile Acid Diarrhoea: A Feasibility Randomised Controlled Trial
NCT06259396 RECRUITING NA
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
NCT00414908 COMPLETED PHASE3
Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
NCT01879735 COMPLETED PHASE1
The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)
NCT07303868 NOT_YET_RECRUITING PHASE4
Expression of BCRP in Icteric Patients
NCT00295360 COMPLETED
The Effect of Physical Properties of Lipid Emulsions on Gastrointestinal Function
NCT01253005 COMPLETED NA
Obeticholic Acid in Bile Acid Diarrhoea
NCT01585025 COMPLETED PHASE2
Bileacid Malabsorption and GLP-1 Secretion
NCT03009916 COMPLETED PHASE4
Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans
NCT03201952 TERMINATED PHASE1
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
NCT00004441 COMPLETED NA
Repetitive Brake Activation
NCT02511366 COMPLETED NA
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
NCT03168555 COMPLETED PHASE4
Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT
NCT03253276 COMPLETED EARLY_PHASE1
Characterization of Fatty Acid Composition of Triglycerides in Patients With Hypertriglyceridemia-induced Acute Pancreatitis
NCT04097990 UNKNOWN NA
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy
NCT03499249 COMPLETED PHASE2
Obeticholic Acid in Morbidly Obese Patients and Healthy Volunteers
NCT02532335 UNKNOWN PHASE1
Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
NCT02871882 COMPLETED PHASE2
Efficacy of Pancrelipase on Postprandial Belching and Bloating.
NCT00266721 COMPLETED PHASE3
Intralumenal Effects on Cholesterol Absorption/Synthesis
NCT00328211 COMPLETED NA
Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study
NCT02916355 COMPLETED NA
Gastric Emptying and Gallbladder Motility Study
NCT00940849 COMPLETED NA
Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)
NCT00570765 COMPLETED PHASE2